Smoking affects the interferon beta treatment response in multiple sclerosis
Citation Manager Formats

Article Information
- Received February 3, 2017
- Accepted in final form November 2, 2017
- First Published January 17, 2018.
Article Versions
- Previous version (January 17, 2018 - 13:10).
- You are viewing the most recent version of this article.
Author Information
- Eva R. Petersen, MD,
- Annette B. Oturai, MD, PhD,
- Nils Koch-Henriksen, MD, DMSc,
- Melinda Magyari, MD, PhD,
- Per S. Sørensen, MD, DMSc,
- Finn Sellebjerg, MD, PhD, DMSc and
- Helle B. Søndergaard, MSc, PhD
- Eva R. Petersen, MD,
I have served on scientific advisory board for Teva (Denmark)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
As mentioned in the manuscript the study was supported by The Danish Multiple Sclerosis Society, the Danish Council for Strategic Research, NOVARTIS, BIOGEN IDEC and The Foundation for Research in Neurology.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Annette B. Oturai, MD, PhD,
(1) Dr. Annette Bang Oturai has served on scientific advisory boards for Sanofi Genzyme and Biogen Idec.
NONE
Has received speaker honoraria from Biogen Idec, Novartis and TEVA; and has received support for congress participation from, Merck Serono, TEVA, Biogen, Novartis and Sanofi Genzyme.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
My laboratory has received research support from Biogen Idec and Novartis.
NONE
NONE
This study was supported by The Danish Multiple Sclerosis Society, the Danish Council for Strategic Research, NOVARTIS, BIOGEN IDEC and The Foundation for Research in Neurology.
NONE
NONE
NONE
NONE
NONE
NONE
- Nils Koch-Henriksen, MD, DMSc,
NONE
NONE
Nils Koch-Henriksen has received travel expenses for attending congresses and meetings from BiogenIdec, Mercx, and TEVA.
Multiple Sclerosis and Related Disorders (since establishment)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Melinda Magyari, MD, PhD,
(1)Biogen (2)Teva (3) Sanofi (3)Roche (4) Merck (5) Novartis
NONE
(1)Biogen (2)Teva (3) Sanofi (4)Novartis
NONE
NONE
NONE
NONE
(1) Roche (2) KORA: Det Nationale Institut for Kommuners og Regioners Analyse og Forskning
NONE
NONE
NONE
(1)Biogen (2)Teva (3) Sanofi (3)Roche (4) Merck (5) Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Per S. Sørensen, MD, DMSc,
Scientific advisory boards for Biogen Idec, Merck, Novartis, Teva Pharmaceutical Industries Ltd., Forward Pharma, MedDay pharmaceuticals, Genzyme, Celgene; Steering committees or independent data monitoring boards in clinical trials sponsored by Merck, Teva Pharmaceutical Industries Ltd., Novartis, and GlaxoSmithKline
NONE
Speaker honoraria from Biogen Idec, Merck, Teva Pharmaceutical Industries Ltd., sanofi-aventis, Genzyme, and Novartis
Previous Editor-in-Chief European Journal of Neurology, Editorial Board: European Journal of Neurology, Therapeutic Advances in Neurological Disorders, Multiple Sclerosis Journal
NONE
NONE
Honoraria for lecturing from Biogen Idec, Merck, TEVA, and Novartis
NONE
NONE
NONE
NONE
The department of Neurology, Rigshospitalet have received unrestricted research grant or compensation for participation in pharmaceutical company sponsored clinical trials from Biogen Idec, Merck, TEVA, Sanofi-aventis/Genzyme, Novartis, RoFAR, and Roche
NONE
NONE
Danish Multiple Sclerosis Society, Danish Medical Research Council, and European Union
NONE
NONE
NONE
NONE
NONE
NONE
- Finn Sellebjerg, MD, PhD, DMSc and
(1) Biogen-Idec (2) Genzyme (3) Merck Serono (4) Sanofi- Aventis (5) Teva (6) Novo Nordisk
NONE
(1) Bayer Schering, speaker honoraria, (2) Biogen Idec, funding for travel and speaker honoraria, (3) Genzyme, speaker honoraria, (4) Merck Serono, speaker honoraria, (5) Novartis, funding for travel and speaker honoraria, (6) Sanofi-Aventis, funding for travel and speaker honoraria (6) Schering-Plough, speaker honoraria (7) Teva, funding for travel 2008 (Teva and Sanofi-Aventis).
Multiple Sclerosis and Related Disorders. Section editor (immunology).
NONE
NONE
NONE
(1) Biogen Idec
NONE
NONE
NONE
Biogen Idec, Sanofi-Aventis, Novartis
Danish Strategic Research Council (2009- 2013), grant number 2142-08-0039.
NONE
(1) Danish Multiple Sclerosis Society (2) Lounk?r Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Helle B. Søndergaard, MSc, PhD
NONE
NONE
Helle Bach S?ndergaard has received support for congress participation from Biogen Idec, Genzyme and Teva.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Sclerose Foreningen, MS networks and immunogenetics, 2015 A.P.M?ller Fonden-Fonden til l?gevidenskabens fremme, MS networks and immunogenetics, 2015
NONE
NONE
NONE
NONE
NONE
NONE
- From the Danish Multiple Sclerosis Center (E.R.P., A.B.O., M.M., P.S.S., F.S., H.B.S.), Department of Neurology, and Danish Multiple Sclerosis Treatment Register (N.K.-H., M.M.), Rigshospitalet, University of Copenhagen; and Department of Clinical Epidemiology (N.K.-H), Clinical Institute, University of Aarhus, Denmark.
- Correspondence
Dr. Petersen Evarosapetersen{at}gmail.com
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.